The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical outcomes and toxicity of estramustine phosphate (EP) addition to docetaxel (D) as first-line therapy for castration-resistant prostate cancer (CRPC): A cumulative analysis on 243 patients (pts) from two randomized phase II trials.
Orazio Caffo
No relevant relationships to disclose
Teodoro Sava
No relevant relationships to disclose
Fable Zustovich
No relevant relationships to disclose
Michele Lodde
No relevant relationships to disclose
Cosimo Sacco
No relevant relationships to disclose
Giovanni Lo Re
No relevant relationships to disclose
Sebastiano Buti
No relevant relationships to disclose
Umberto Basso
No relevant relationships to disclose
Teresa Gamucci
No relevant relationships to disclose
Gaetano Facchini
No relevant relationships to disclose
Alessandra Perin
No relevant relationships to disclose
Romana Segati
No relevant relationships to disclose
Lucianna Russo
No relevant relationships to disclose
Antonello Veccia
No relevant relationships to disclose
Enzo Galligioni
No relevant relationships to disclose